Report Title:
PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026 Published On: November 2017
Category: Life Sciences
Pages: 413
Report Overview: PharmaPoint: Prostate Cancer Global Drug Forecast and Market Analysis to 2026 Summary The prostate cancer market is expected to experience a moderate growth between 2016 and 2026. The main drivers of growth will be the expected label expansion of secondgeneration hormonal agents into hormonesensitive disease and nonmetastatic castration resistant prostate cancer nmCRPC, and the launch and uptake of nine new premiumpriced therapies. Until now, the hormone sensitive setting has been dominated by the use of cheap firstgeneration hormonal agents, with the use of premiumpriced secondgeneration hormonal agents Xtandi and Zytiga limited to metastatic CRPC. The prostate cancer competitive landscape is going to experience a substantial change. Given that Zytiga and Xtandi are limited by the insurgence of acquired resistance, physicians will face the critical issue of determining the best treatment sequence for subsequent lines of therapy, most notably in the mCRPC setting. Additionally, companies are now moving toward a more personalized approach in prostate cancer, targeting mCRPC patients with specific genetic signatures, such as PTEN loss and DNA repair abnormalities. GlobalData expects these biomarkerdriven drug development strategies to induce further patient stratification and to add complexity to the CRPC treatment algorithm. Scope Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled. Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global prostate cancer market. Drive revenues by understanding the key trends, innovative products and
24marketreports | International +1 646 781 7170 | www.24marketreports.com
technologies, market segments, and companies likely to impact the global prostate cancer market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents: 1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 8 1.2 List of Figures 11 2 Prostate Cancer: Executive Summary 13 2.1 Value of Prostate Cancer Market to Increase TwoFold By 2026 14 2.2 Xtandi to Become the Undisputed Leader in the Global Prostate Cancer Market 16 2.3 Prostate Cancer Treatment Landscape to Undergo Dramatic Change 18 2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine 18 2.5 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response 20 2.6 What Do the Physicians Think? 20 3 Introduction 23 3.1 Catalyst 23 3.2 Related Reports 24 3.3 Upcoming Related Reports 24 4 Disease Overview 25 4.1 Etiology and Pathophysiology 25 4.1.1 Etiology 25 4.1.2 Pathophysiology 26 4.1.3 Biomarkers 27 4.2 Classification or Staging Systems 29 4.3 Symptoms 31 4.4 Prognosis 31 4.5 Quality of Life 31 5 Epidemiology 33 5.1 Disease Background 33 5.2 Risk Factors and Comorbidities 33 5.3 Global and Historical Trends 35 5.3.1 US 36 5.3.2 5EU 37 5.3.3 Japan 37
24marketreports | International +1 646 781 7170 | www.24marketreports.com
5.4 Forecast Methodology 37 5.4.1 Sources Used 38 5.4.2 Forecast Assumptions and Methods 43 5.5 Epidemiological Forecast for Prostate Cancer 20162026 52 5.5.1 Diagnosed Incident Cases of Prostate Cancer 52 5.5.2 AgeSpecific Incident Cases of Prostate Cancer 53 5.5.3 Incident Cases by Stage at Diagnosis 54 5.5.4 Incident Cases by Risk of Biochemical Recurrence 55 5.5.5 10Year Diagnosed Prevalent Cases of Prostate Cancer 56 5.5.6 10Year Prevalent CRPC Cases 57 5.5.7 10Year Prevalent Metastatic Prostate Cancer Cases 58 5.5.8 10Year Prevalent mCRPC Cases with HRD Mutations 59 5.6 Discussion 60 5.6.1 Epidemiological Forecast Insight 60 5.6.2 Limitations of Analysis 62 5.6.3 Strengths of Analysis 62 6 Disease Management 63 6.1 Diagnosis Overview 63 6.2 Treatment Overview 66 6.2.1 Treatment Guidelines and Leading Prescribed Drugs 66 6.2.2 Clinical Practice 67 6.3 US 90 6.3.1 Diagnosis 90 6.3.2 Clinical Practice 92 6.4 France 94 6.4.1 Diagnosis 95 6.4.2 Clinical Practice 95 6.5 Germany 98 6.5.1 Diagnosis 98 6.5.2 Clinical Practice 99 6.6 Italy 102 6.6.1 Diagnosis 102 6.6.2 Clinical Practice 103 6.7 Spain 105 6.7.1 Diagnosis 105 6.7.2 Clinical Practice 105 6.8 UK 107 6.8.1 Screening and Diagnosis 107 6.8.2 Clinical Practice 108 6.9 Japan 111 6.9.1 Diagnosis 111 6.9.2 Clinical Practice 112 7 Competitive Assessment 115 7.1 Overview 115 7.2 SecondGeneration Hormonal Therapies 117 7.2.1 Zytiga Abiraterone Acetate 117
24marketreports | International +1 646 781 7170 | www.24marketreports.com
7.2.2 Xtandi Enzalutamide 127 7.3 Targeted Therapies 139 7.3.1 Xofigo Radium 223 Dichloride 139 7.4 Chemotherapies 146 7.4.1 Jevtana Cabazitaxel 146 7.5 Therapeutic Vaccines 151 7.5.1 Provenge SipuleucelT 151 7.6 FirstGeneration Hormonal Therapies 160 7.6.1 Zoladex Goserelin Acetate 160 7.6.2 Lupron Depot Leuprolide Acetate 164 7.6.3 Eligard Leuprolide Acetate 167 7.6.4 Trelstar Triptorelin Pamoate 171 7.6.5 Vantas Histrelin Acetate 174 7.6.6 Firmagon Degarelix 177 7.6.7 Casodex Bicalutamide 182 7.7 Bone Therapies 186 7.7.1 Zometa Zoledronic Acid 186 7.7.2 Xgeva Denosumab 189 8 Unmet Needs and Opportunity Assessment 193 8.1 Overview 193 8.2 Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients 195 8.2.1 Unmet Need 195 8.2.2 Gap Analysis 195 8.2.3 Opportunity 197 8.3 Therapeutic Options for NonMetastatic CRPC 198 8.3.1 Unmet Need 198 8.3.2 Gap Analysis 198 8.3.3 Opportunity 199 8.4 Identification of Biomarkers to Predict Zytiga and Xtandi Resistance and Agents Able to Overcome Resistanceto Available Therapies 200 8.4.1 Unmet Need 200 8.4.2 Gap Analysis 201 8.4.3 Opportunity 202 8.5 Identification of New Targets and Positive Predictive Biomarkers of Response 203 8.5.1 Unmet Need 203 8.5.2 Gap Analysis 204 8.5.3 Opportunity 205 9 Pipeline Assessment 207 9.1 Overview 207 9.2 Promising Drugs in Clinical Development 213 9.3 Immunotherapies 216 9.3.1 ProstAtak Aglatimagene Besadenovec 216 9.3.2 Stapuldencelt DCVAC/PCa 223 9.3.3 ITK1 229 9.3.4 Tecentriq Atezolizumab 234 9.4 SecondGeneration Hormonal Therapies 239
24marketreports | International +1 646 781 7170 | www.24marketreports.com
9.4.1 Apalutamide ARN509 239 9.4.2 Darolutamide ODM201 248 9.5 Targeted Therapies 256 9.5.1 Masitinib AB1010 256 9.5.2 Lynparza Olaparib 260 9.5.3 Rubraca Rucaparib Camsylate 268 9.5.4 Ipatasertib GDC0068 274 9.6 FirstGeneration Hormonal Therapies 281 9.6.1 Relugolix TAK385 281 9.7 Promising Drugs in EarlyStage Development 287 9.7.1 Targeting the P13K/AKT/mTOR Pathway 287 9.7.2 Immunotherapies 288 9.7.3 ProstateSpecific Membrane AntigenTargeted Therapies 293 9.7.4 Hormonal Therapies 297 9.8 Other Drugs in Development 300 10 Current and Future Players 303 10.1 Overview 303 10.2 Trends in Corporate Strategy 307 10.3 Company Profiles 310 10.3.1 Astellas 310 10.3.2 AstraZeneca 312 10.3.3 Bayer 314 10.3.4 Clovis Oncology 316 10.3.5 Johnson & Johnson 318 10.3.6 Pfizer 321 10.3.7 Roche 323 10.3.8 Sanofi 325 11 Market Outlook 326 11.1 Global Markets 326 11.1.1 Forecast 326 11.1.2 Drivers and Barriers Global Issues 330 11.2 US 331 11.2.1 Forecast 331 11.2.2 Key Events 333 11.2.3 Drivers and Barriers 334 11.3 5EU 335 11.3.1 Forecast 335 11.3.2 Key Events 337 11.3.3 Drivers and Barriers 338 11.4 Japan 340 11.4.1 Forecast 340 11.4.2 Key Events 342 11.4.3 Drivers and Barriers 343 12 Appendix 344 12.1 Bibliography 344 12.2 Abbreviations 379
24marketreports | International +1 646 781 7170 | www.24marketreports.com
12.3 Methodology 386 12.3.1 Forecasting Methodology 386 12.3.2 Diagnosed Prostate Cancer Patients 386 12.3.3 Percent DrugTreated Patients 387 12.3.4 Drugs Included in Each Therapeutic Class 387 12.3.5 Launch and Patent Expiry Dates 387 12.3.6 General Pricing Assumptions 389 12.3.7 Individual Drug Assumptions 391 12.3.8 Generic Erosion 402 12.4 Primary Research KOLs Interviewed for This Report 403 12.5 Primary Research Prescriber Survey 407 12.6 About the Authors 408 12.6.1 Analyst 408 12.6.2 Therapy Area Director 408 12.6.3 Epidemiologist 409 12.6.4 Epidemiology Reviewers 409 12.6.5 Global Director of Therapy Analysis and Epidemiology 410 12.6.6 Global Head and EVP of Healthcare Operations and Strategy 411 12.7 About GlobalData 412 12.8 Contact Us 412 12.9 Disclaimer 413
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/pharmapointprostate-cancer-drug-forecast-mar ket-91 To get Report Sample: https://www.24marketreports.com/request-sample/pharmapointprostate-cancer-drug-forecastmarket-91
24marketreports | International +1 646 781 7170 | www.24marketreports.com